# Spruce Capital Partners

> Spruce Capital Partners is a VC fund backing Biotechnology and Agriculture. See 15 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 15
- Last investment: May 2022
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/spruce-capital-partners-llc/
- Website: http://www.sprucecp.com/

Spruce Capital Partners is a VC fund in San Francisco focused on Biotechnology and Agriculture. The principals of Spruce Capital Partners are well known investors and thought leaders in the biogreentech sector. They bring a wealth of experience as investors, advisers, and domain experts in helping entrepreneurs build the next generation of successful biogreentech companies. They formed Spruce Capital Partners not only to manage venture funds,but also to develop new talent for the industry, provide thought leadership, and promote innovation in companies and countries. The principals have worked together for more than 10 years and have shepherded investments across multiple funds and multiple sectors. The principals of Spruce Capital Partners are also active in advising, partnering, and shaping the life sciences industry globally and, especially in Malaysia and United States.

## Contacts

5 contacts available for Spruce Capital Partners. Shizune tracks 3 team members at Spruce Capital Partners. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/spruce-capital-partners?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 6 | 40% |
| Agriculture | 5 | 33% |
| Health Care | 3 | 20% |
| AgTech | 2 | 13% |
| Chemical | 2 | 13% |

28 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 5 | 33% |
| Series C | 3 | 20% |
| Series A | 2 | 13% |
| Series D | 2 | 13% |
| Funding Round | 1 | 7% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 9 | 60% |
| Israel | 1 | 7% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Ganesh Kishore | Managing Partner & Co-Founder | 9 | — |
| Greg Young | Managing Partner & Co-Founder | 0 | — |
| Roger Wyse | Managing Partner & Co-FOunder | 4 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| A.Team | A.Team builds proprietary agentic intelligence systems for consumer-facing enterprises, turning fragmented data, institutional knowledge, and historical decisions into a single self-improving intelligence layer that compounds over time.Unlike generic AI platforms, A.Team deploys a custom intelligence system inside your environment, trained onyour data, campaigns, and outcomes. Forward-deployed engineers with an average of 18 years of experience from leading technology companies build and operate the system alongside client teams, embedding it directly into existing workflows without requiring new platforms or logins.Enterprises that work with A.Team compress the insight-to-action cycle from days to hours, shift marketing teams from data assembly to strategic thinking, and build a proprietary intelligence asset that grows more valuable with every decision made.A.Team's reusable AI middleware (Assemble) enables first insights in 48 hours and measured value in 90 days. The system is model-agnostic, fully owned by the client, and designed so intelligence persists regardless of vendor relationship.A.Team serves CMOs, Chief Growth Officers, and senior marketing leaders at consumer-facing enterprises with $100M+ in marketing spend across CPG, retail, food and beverage, entertainment, media, tech, automotive, and travel. | $55M | Series A | May 17, 2022 |  |
| Greenlight Biosciences | GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $125.5M | Post-IPO Equity | Feb 03, 2022 |  |
| Amfora | Amfora is a biotechnology company that is harnessing biology to sustainably nourish the world’s population and enhancing wellness. Amfora's mission is to meet the growing global demand for foods that are high in protein by enhancing the nutritional density of food and feed crops, while reducing the cost of food and the environmental toll onthe planet. | $6M | Series B | Mar 23, 2021 |  |
| Provivi | Provivi is developing biopesticides for agriculture, commercial, household, and public health pest management. It has a world-class team of founders, scientists, and advisors with significant experience in biotechnology (including biocatalysis), the fine chemicals industry, and, in particular, the agchem industry. It pursues disruptiveopportunities enabled by breakthrough biological processes for making supply-limited products that are efficacious, safe, and environmentally benign.Provivi was founded in 2013 based on biocatalysis technology developed at the California Institute of Technology (Caltech) which has since become a licensor, shareholder, and research collaborator. It is based in Santa Monica, California. | $45.5M | Series C | Dec 22, 2020 |  |
| Greenlight Biosciences | GreenLight Biosciences is an integrated life sciences company with a cutting-edge platform to deliver higher-quality RNA at a lower cost and more quickly than was ever before possible. GreenLight develops RNA products and collaborates with industry leaders to advance vaccine development, pandemic preparation, crop management, plant protection andsupport the health of bees and other pollinators. | $102M | Series D | Jun 16, 2020 |  |
| Pivot Bio | Pivot Bio is improving and using a deep understanding of the microbiome to advance crop nutrition. They believe that microbes can deliver nutrients, protect against pests, and improve crop quality better than chemical fertilizers and pesticides. They leverage engineering principles and data science to map the dynamics of the plant microbiome andevolve beneficial traits. Their team thrives on collaboration and communication as they seek to create revolutionary fertilizers that transform food supply and improves the planet.Pivot Bio's proprietary ON Technology harnesses the power of naturally occurring microbes to provide more nutrients to crops. It’s a smart, sustainable way for farmers to improve yield as they work to help feed the world’s growing population. Their current efforts are focused on enabling microbes to fix and supply more nitrogen to corn.Pivot Bio was founded in 2010 and is headquartered in Berkeley, California, United States. | $100M | Series C | Apr 30, 2020 |  |
| Crop Enhancement | Crop Enhancement develop a new approach that will help farmers increase crop yields and profitability in a sustainable way. By developing agrochemical formulations that employ advanced and environmentally friendly chemistry, we help improve crop yields, eliminate or minimize pesticide use, and enable precise and effective delivery of activeingredients and fertilizers. | $8M | Series B | Apr 14, 2020 |  |
| Provivi | Provivi is developing biopesticides for agriculture, commercial, household, and public health pest management. It has a world-class team of founders, scientists, and advisors with significant experience in biotechnology (including biocatalysis), the fine chemicals industry, and, in particular, the agchem industry. It pursues disruptiveopportunities enabled by breakthrough biological processes for making supply-limited products that are efficacious, safe, and environmentally benign.Provivi was founded in 2013 based on biocatalysis technology developed at the California Institute of Technology (Caltech) which has since become a licensor, shareholder, and research collaborator. It is based in Santa Monica, California. | $85M | Series C | Oct 15, 2019 |  |
| Consumer Physics | Consumer Physics is driven by a mission to empower consumers and businesses to learn about the makeup of materials anytime, anywhere by using SCiO, the smallest near-infrared (NIR) spectrometer.The SCiO sensor pairs with SCiO smartphone apps and connects to a cloud-based database of material fingerprints. Consumer Physics offers businesses and3rd party developers a platform that enables them to design their own molecular sensing models and mobile applications for personal and commercial use. The SCiO DevKit includes the SCiO Lab development platform and Mobile SDK and access to professional support from Consumer Physics experts. | $668.8K |  | Jul 03, 2018 |  |
| Inscripta | Inscripta is developing the first benchtop platform for scalable digital genome engineering. The company’s advanced CRISPR-based platform, consisting of an instrument, consumables, software, and assays, offers a fully automated workflow that enables massively parallel, trackable editing of single cells at an unprecedented scale. Inscripta’s goal isto empower scientists whose gene editing research is stifled by current technical and licensing limitations. By providing this unique platform and engaging in collaborative business practices, such as making its MAD7 CRISPR nuclease-free for research and development purposes, the company enables scientists to realize a new era of biological discovery. | $55.5M | Series C | Feb 28, 2018 |  |

10 of 15 investments shown.

## Co-investors
- [Continental Grain Company](https://shizune.co/investors/profile/continental-grain-company) — VC Fund, 3 deals together
- [Kairos Ventures](https://shizune.co/investors/profile/kairos-venture-investments-llc) — VC Fund, 3 deals together
- [Temasek](https://shizune.co/investors/profile/temasek) — VC Fund, 3 deals together
- [Aliment Capital](https://shizune.co/investors/profile/aliment-capital) — VC Fund, 2 deals together
- [BASF Venture Capital](https://shizune.co/investors/profile/basf-venture-capital) — VC Fund, 2 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does Spruce Capital Partners invest in?

Spruce Capital Partners invests primarily in Biotechnology, Agriculture and Health Care startups, most often at Series B and Series C stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Spruce Capital Partners?

Public channels for Spruce Capital Partners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Spruce Capital Partners?

The team at Spruce Capital Partners includes Ganesh Kishore (Managing Partner & Co-Founder), Greg Young (Managing Partner & Co-Founder) and Roger Wyse (Managing Partner & Co-FOunder). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co